Group 1 - The company held an investor reception day and mid-year performance briefing on September 19, 2023, with key management present [1] - Investors raised questions regarding new drug development, market expansion, and production capacity, to which the management provided detailed responses [2] - The company has established a commercial partnership with Sinovac Biotech for the overseas expansion of its drug, Anglatavir, in Macau and is actively pursuing international clinical applications and registrations [2] Group 2 - The company is the only domestic entity with innovative drugs for both COVID-19 and influenza, focusing on the commercialization of its products, Le Ruiling® and An Ruivei® [2] - The company is enhancing its marketing strategies through academic ecosystem development, data service upgrades, and key project practices to increase market share [2] - Ongoing clinical trials include RAY1225 for obesity, ZSP1601 for metabolic dysfunction-related fatty liver disease, and the commercialization of cyclosporine eye drops [2][3] Group 3 - Investors inquired about the company's overseas market development plans, traditional Chinese medicine growth, innovative drug insurance negotiations, stock performance, share buybacks, and executive shareholding [3] - The management assured compliance with relevant laws and regulations and emphasized timely information disclosure [3]

Group 1: New Drug Development and Market Expansion - The company has established a commercial partnership with Sinovac Biotech for the marketing of Anglave tablets in Macau, aiming to enhance its international presence [2] - Anglave, as the world's first PB2 inhibitor, shows significant efficacy against resistant strains, supported by endorsements from prominent experts [4] - The company is actively seeking domestic partners to expand into Hong Kong and ASEAN markets [4] Group 2: Production Capacity and Market Demand - The company has sufficient tablet production capacity and can adjust production based on market demand [2] - The potential market for Anglave is substantial, with optimistic projections suggesting it could outperform Oseltamivir, which generated over $3 billion in sales last year [6] Group 3: Financial Performance and Stock Market - The company's stock price has increased by 65.36% year-to-date, reflecting investor confidence in its transition to innovative drug development [15] - The company aims to maintain a stable development trajectory and enhance its market value through continuous innovation and effective management [28] Group 4: Clinical Trials and Regulatory Approvals - The company is progressing with the clinical trials for ZSP1601, a new drug for treating metabolic dysfunction-related fatty liver disease, currently in Phase IIb trials [13] - The company is also advancing the clinical trials for Anglave granules, targeting a significant pediatric and elderly patient population [15] Group 5: Strategic Focus and Future Outlook - The company emphasizes the importance of traditional Chinese medicine as a revenue source while pursuing innovative drug development for sustainable growth [15] - The management is committed to enhancing the company's reputation and visibility in the capital market to support its innovative drug initiatives [28]